Glaxosmi.-Pharma Stock/Share Prices, Buy and Sell Glaxosmi.-Pharma BSE Stocks

Glaxosmithkline Pharmaceuticals Ltd NSE / BSE
Pharmaceuticals, Large Cap

Invest

21 Aug 2018 | 01:51 PM

3,326.00

-30.05 (-0.90%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

39.67%

Return (1Y)

Beaten S&P BSE Healthcare by 20.8%
More Volatile

1.37%

Standard Deviation (1Y)

Higher than S&P BSE Healthcare by 0.31%
Consistent Performer

7/12

Months

beaten S&P BSE Healthcare
AxisDirect View

No View

52 Week High-Low

3,399

2,040

News & Announcements

Glaxosmithkline Pharmaceuticals standalone net profit rises 235.31% in the June 2018 quarter
26 days ago

Glaxosmithkline Pharmaceuticals standalone net profit rises 235.31% in the June 2018 quarter

25 - Jul - 2018 12:00 AM | 26 days ago

Net profit of Glaxosmithkline Pharmaceuticals rose 235.31% to Rs 88.59 crore in the quarter ended June 2018 as against Rs 26.42 crore during the previous quarter ended June 2017. Sales rose 26.21% to Rs 735.65 crore in the quarter ended June 2018 as against Rs 582.90 crore during the previous quarter ended June 2017.
Particulars Quarter Ended
Jun. 2018 Jun. 2017 % Var.
Sales 735.65 582.90 26
OPM % 19.08 3.38 -
PBDT 157.95 33.34 374
PBT 146.59 25.82 468
NP 88.59 26.42 235
Powered by Capital Market - Live News
Board of Glaxosmithkline Pharmaceuticals recommends bonus issue of 1:1
27 days ago

Board of Glaxosmithkline Pharmaceuticals recommends bonus issue of 1:1

24 - Jul - 2018 12:00 AM | 27 days ago

The Board of Glaxosmithkline Pharmaceuticals has recommended bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals.
The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted.
Powered by Capital Market - Live News
Glaxosmithkline Pharmaceuticals announces cessation of directors
27 days ago

Glaxosmithkline Pharmaceuticals announces cessation of directors

24 - Jul - 2018 12:00 AM | 27 days ago

Glaxosmithkline Pharmaceuticals announced that Marc Jones, Non-Executive Director and Rajeshwar R. Bajaaj, Independent Director have ceased to be a Directors of the Company from close of the business hours on 24 July 2018.
Powered by Capital Market - Live News
GlaxoSmithKline Pharmaceuticals to convene board meeting
55 days ago

GlaxoSmithKline Pharmaceuticals to convene board meeting

27 - Jun - 2018 12:00 AM | 55 days ago

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 July 2018.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Glaxosmithkline Pharma Ltd is trading very close to its 52 Week High
MF shareholding in Glaxosmithkline Pharma Ltd has increased by 7.28% since past 3 Months
FII shareholding in Glaxosmithkline Pharma Ltd has decreased by -11.1% since past 1 Year
MF shareholding in Glaxosmithkline Pharma Ltd has increased by 44.47% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Jun. 2018	Jun. 2017	% Var.
Sales	735.65	582.90	26
OPM %	19.08	3.38	-
PBDT	157.95	33.34	374
PBT	146.59	25.82	468
NP	88.59	26.42	235

General Notifications

My Notifications

Research Notifications

Glaxosmithkline Pharmaceuticals Ltd NSE / BSE Pharmaceuticals, Large Cap

3,326.00 -30.05 (-0.90%)

News & Announcements

Price vs Volume

Stock Trivia

Glaxosmithkline Pharmaceuticals Ltd NSE / BSE
Pharmaceuticals, Large Cap

3,326.00

-30.05 (-0.90%)